OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in bioengineering and biotechnology
2021;9 707319.

Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy.

Di Chang, Yuanyuan Ma, Xiaoxuan Xu, Jinbing Xie, Shenghong Ju
Author Information
  1. Di Chang: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
  2. Yuanyuan Ma: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
  3. Xiaoxuan Xu: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
  4. Jinbing Xie: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
  5. Shenghong Ju: Jiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, China.
PMID: 34249894 DOI: 10.3389/fbioe.2021.707319

Abstract

Polymeric nanoparticles have been widely used as carriers of drugs and bioimaging agents due to their excellent biocompatibility, biodegradability, and structural versatility. The principal application of polymeric nanoparticles in medicine is for cancer therapy, with increased tumor accumulation, precision delivery of anticancer drugs to target sites, higher solubility of pharmaceutical properties and lower systemic toxicity. Recently, the stimuli-responsive polymeric nanoplatforms attracted more and more attention because they can change their physicochemical properties responding to the stimuli conditions, such as low pH, enzyme, redox agents, hypoxia, light, temperature, magnetic field, ultrasound, and so on. Moreover, the unique properties of stimuli-responsive polymeric nanocarriers in target tissues may significantly improve the bioactivity of delivered agents for cancer treatment. This review introduces stimuli-responsive polymeric nanoparticles and their applications in tumor theranostics with the loading of chemical drugs, nucleic drugs and imaging molecules. In addition, we discuss the strategy for designing multifunctional polymeric nanocarriers and provide the perspective for the clinical applications of these stimuli-responsive polymeric nanoplatforms.

Keywords

cancer therapy nanomedicine polymeric nanoparticle stimuli-responsive theranostic

References

  1. Nanoscale. 2017 Oct 5;9(38):14627-14634 [PMID: 28936509]
  2. Adv Mater. 2021 Apr;33(14):e2008061 [PMID: 33634897]
  3. Int J Nanomedicine. 2008;3(2):133-49 [PMID: 18686775]
  4. ACS Appl Mater Interfaces. 2015 May 20;7(19):10132-45 [PMID: 25840122]
  5. J Pharm Bioallied Sci. 2014 Jul;6(3):139-50 [PMID: 25035633]
  6. Chem Soc Rev. 2017 Jun 21;46(12):3830-3852 [PMID: 28516983]
  7. Small. 2014 Feb 12;10(3):566-75, 417 [PMID: 24038954]
  8. Chem Soc Rev. 2019 Apr 1;48(7):2053-2108 [PMID: 30259015]
  9. Oncotarget. 2016 Dec 13;7(50):82170-82184 [PMID: 27366951]
  10. Signal Transduct Target Ther. 2018 Mar 16;3:7 [PMID: 29560283]
  11. Angew Chem Int Ed Engl. 2019 Apr 23;58(18):5920-5924 [PMID: 30793456]
  12. Theranostics. 2014 Jan 29;4(4):399-411 [PMID: 24578723]
  13. Mol Pharm. 2012 Sep 4;9(9):2469-78 [PMID: 22827551]
  14. ACS Nano. 2015 May 26;9(5):5234-45 [PMID: 25859611]
  15. ACS Nano. 2020 Nov 18;: [PMID: 33206522]
  16. Nat Rev Drug Discov. 2014 Dec;13(12):904-27 [PMID: 25376097]
  17. Nanomaterials (Basel). 2021 Mar 16;11(3): [PMID: 33809764]
  18. Nat Rev Drug Discov. 2021 Feb;20(2):101-124 [PMID: 33277608]
  19. Angew Chem Int Ed Engl. 2017 Nov 6;56(45):14025-14030 [PMID: 28940903]
  20. Biomaterials. 2013 Jul;34(21):5163-71 [PMID: 23591395]
  21. Pharm Res. 2016 Oct;33(10):2373-87 [PMID: 27299311]
  22. Chem Rev. 2015 Feb 25;115(4):1990-2042 [PMID: 25602130]
  23. J Control Release. 2017 Aug 10;259:40-52 [PMID: 28288893]
  24. Science. 2013 Feb 1;339(6119):535-9 [PMID: 23372006]
  25. ACS Nano. 2016 Mar 22;10(3):2991-4 [PMID: 26881288]
  26. Acc Chem Res. 2020 Apr 21;53(4):752-762 [PMID: 32027481]
  27. Pharm Res. 2010 Dec;27(12):2569-89 [PMID: 20725771]
  28. Adv Mater. 2016 Sep;28(34):7340-64 [PMID: 27255214]
  29. Chem Soc Rev. 2015 Jun 21;44(12):4091-130 [PMID: 25902871]
  30. Expert Opin Drug Deliv. 2017 Jan;14(1):75-92 [PMID: 27339650]
  31. Biomaterials. 2014 Aug;35(26):7622-34 [PMID: 24929619]
  32. Pharm Res. 2016 Oct;33(10):2358-72 [PMID: 27183840]
  33. Adv Mater. 2018 May;30(18):e1706356 [PMID: 29468747]
  34. Curr Opin Biotechnol. 2016 Aug;40:41-48 [PMID: 26938687]
  35. Chem Rev. 2016 Jun 22;116(12):6743-836 [PMID: 27299693]
  36. Eur J Pharm Biopharm. 2009 Mar;71(3):409-19 [PMID: 19070661]
  37. Biomaterials. 2014 Mar;35(9):3080-90 [PMID: 24388799]
  38. Cancer Res. 2010 Mar 15;70(6):2180-90 [PMID: 20215497]
  39. Cancers (Basel). 2011 Jan 20;3(1):408-14 [PMID: 24310355]
  40. Acc Chem Res. 2011 Oct 18;44(10):1061-70 [PMID: 21932809]
  41. Biomaterials. 2015 Dec;73:214-30 [PMID: 26410788]
  42. J Control Release. 2017 Dec 10;267:67-79 [PMID: 28888917]
  43. Cancer Chemother Pharmacol. 2014 Aug;74(2):277-82 [PMID: 24906423]
  44. Trends Biotechnol. 2006 Jan;24(1):39-47 [PMID: 16307811]
  45. ACS Nano. 2016 Jun 28;10(6):5947-58 [PMID: 27285378]
  46. Adv Drug Deliv Rev. 2019 Jan 1;138:18-40 [PMID: 30321621]
  47. Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2104-13 [PMID: 27036008]
  48. Exp Biol Med (Maywood). 2016 May;241(9):972-9 [PMID: 27188515]
  49. Adv Drug Deliv Rev. 2017 Jan 15;109:84-101 [PMID: 26712711]
  50. Acta Biomater. 2017 Feb;49:422-433 [PMID: 27890622]
  51. Chem Commun (Camb). 2014 Oct 11;50(79):11614-30 [PMID: 25058003]
  52. ACS Nano. 2011 Jun 28;5(6):5202-13 [PMID: 21627074]
  53. Adv Drug Deliv Rev. 2019 Jan 1;138:133-147 [PMID: 30321619]
  54. Biomaterials. 2014 Feb;35(5):1735-43 [PMID: 24290696]
  55. Biomaterials. 2016 Apr;85:152-67 [PMID: 26871891]
  56. J Am Chem Soc. 2013 Dec 18;135(50):18710-3 [PMID: 24308273]
  57. J Am Chem Soc. 2014 Apr 16;136(15):5647-55 [PMID: 24689550]
  58. Nano Lett. 2017 May 10;17(5):2871-2878 [PMID: 28375632]
  59. Heliyon. 2018 Dec 22;4(12):e01071 [PMID: 30603704]
  60. Int J Nanomedicine. 2018 May 18;13:2921-2942 [PMID: 29849457]
  61. Chem Soc Rev. 2017 Jan 3;46(1):158-196 [PMID: 27841412]
  62. Theranostics. 2016 Jun 15;6(9):1336-52 [PMID: 27375783]
  63. Cancer Discov. 2021 Apr;11(4):933-959 [PMID: 33811125]
  64. Biomacromolecules. 2015 Feb 9;16(2):447-56 [PMID: 25565417]
  65. Chem Rev. 2016 Feb 24;116(4):2602-63 [PMID: 26854975]
  66. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  67. Nano Lett. 2016 Dec 14;16(12):7357-7363 [PMID: 27960523]
  68. Adv Sci (Weinh). 2016 Jun 08;4(1):1600124 [PMID: 28105390]
  69. J Control Release. 2015 Apr 28;204:85-97 [PMID: 25744825]
  70. Colloids Surf B Biointerfaces. 2021 Aug;204:111778 [PMID: 33915380]
  71. Nat Commun. 2018 Apr 12;9(1):1410 [PMID: 29650952]
  72. Nat Rev Cancer. 2017 Jan;17(1):20-37 [PMID: 27834398]
  73. ACS Nano. 2018 Jan 23;12(1):662-670 [PMID: 29271636]
  74. J Control Release. 2016 Oct 28;240:67-76 [PMID: 26514292]
  75. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):830-8 [PMID: 17379450]
  76. Adv Mater. 2014 Dec 23;26(48):8154-62 [PMID: 25331930]
  77. Adv Healthc Mater. 2014 Aug;3(8):1230-9 [PMID: 24550203]
  78. Biomaterials. 2014 Mar;35(10):3467-79 [PMID: 24439418]
  79. Mol Cancer Ther. 2009 Oct;8(10):2861-71 [PMID: 19825804]
  80. Acc Chem Res. 2011 Oct 18;44(10):1039-49 [PMID: 21608994]
  81. Biomaterials. 2018 Feb;156:217-237 [PMID: 29207323]
  82. Front Bioeng Biotechnol. 2018 Aug 13;6:110 [PMID: 30159310]
  83. Macromol Biosci. 2010 Oct 8;10(10):1248-56 [PMID: 20593367]
  84. Biomaterials. 2013 May;34(14):3647-57 [PMID: 23415642]
  85. Nanoscale. 2014 Nov 7;6(21):12273-86 [PMID: 25251024]
  86. Nano Lett. 2017 Nov 8;17(11):6983-6990 [PMID: 28977746]
  87. Magn Reson Med. 2006 Oct;56(4):761-7 [PMID: 16902981]
  88. Macromol Biosci. 2010 Mar 10;10(3):239-45 [PMID: 19924685]
  89. Expert Opin Drug Deliv. 2008 Oct;5(10):1077-91 [PMID: 18817514]
  90. J Control Release. 2015 Jun 10;207:131-42 [PMID: 25883030]
  91. Chem Soc Rev. 2015 Jun 21;44(12):3874-89 [PMID: 25336064]
  92. Pharm Res. 2014 Jun;31(6):1358-76 [PMID: 23765400]
  93. Adv Drug Deliv Rev. 2013 May;65(5):663-76 [PMID: 22613038]
  94. ACS Nano. 2015 Dec 22;9(12):12451-63 [PMID: 26495962]
  95. Theranostics. 2012;2(12):1117-26 [PMID: 23382770]
  96. ACS Nano. 2012 Aug 28;6(8):7340-51 [PMID: 22838646]
  97. Biomater Res. 2018 Aug 23;22:22 [PMID: 30155269]
  98. Nat Rev Immunol. 2013 Sep;13(9):649-65 [PMID: 23969736]
  99. Pharmaceutics. 2020 Jul 04;12(7): [PMID: 32635539]
  100. Nat Chem. 2020 Apr;12(4):381-390 [PMID: 32152477]
  101. Chem Soc Rev. 2014 Sep 21;43(18):6570-97 [PMID: 24792930]
  102. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79 [PMID: 20691229]
  103. Drug Discov Today. 2015 Sep;20(9):1143-51 [PMID: 26007605]
  104. Curr Med Chem. 2018 Feb 13;25(5):606-635 [PMID: 28990515]
  105. Invest New Drugs. 2011 Oct;29(5):1029-37 [PMID: 20179989]
  106. Chem Soc Rev. 2018 Jul 30;47(15):5554-5573 [PMID: 29856446]
  107. Angew Chem Int Ed Engl. 2014 Sep 1;53(36):9550-4 [PMID: 25045009]
  108. Adv Mater. 2018 Apr;30(17):e1705674 [PMID: 29450915]
  109. Adv Drug Deliv Rev. 2013 Dec;65(15):1964-2015 [PMID: 23954402]
  110. Biomaterials. 2017 Nov;145:138-153 [PMID: 28863308]
  111. Saudi Pharm J. 2020 Mar;28(3):255-265 [PMID: 32194326]
  112. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S189-99 [PMID: 16113096]
  113. Adv Drug Deliv Rev. 2012 Jun 15;64(9):866-84 [PMID: 22349241]
  114. ACS Nano. 2011 Nov 22;5(11):8710-20 [PMID: 21970766]
  115. Adv Drug Deliv Rev. 2016 Mar 1;98:99-112 [PMID: 26748259]
  116. Chem Soc Rev. 2016 Mar 7;45(5):1457-501 [PMID: 26776487]
  117. Nanoscale. 2017 Mar 9;9(10):3637-3645 [PMID: 28247895]
  118. Mini Rev Med Chem. 2017;17(18):1746-1757 [PMID: 26891932]
  119. Adv Mater. 2014 Jun 4;26(21):3433-40 [PMID: 24677423]
  120. Nat Rev Cancer. 2004 Jun;4(6):437-47 [PMID: 15170446]
  121. Adv Mater. 2019 May;31(21):e1806444 [PMID: 30907469]
  122. Adv Drug Deliv Rev. 2019 Jan 1;138:56-67 [PMID: 30414494]
  123. Acc Chem Res. 2011 Oct 18;44(10):1094-104 [PMID: 21812415]
  124. ACS Nano. 2021 Jan 26;15(1):1627-1639 [PMID: 33356128]
  125. Nat Rev Drug Discov. 2019 Apr;18(4):273-294 [PMID: 30542076]
  126. Adv Drug Deliv Rev. 2014 Jul;74:35-52 [PMID: 24993612]
  127. Angew Chem Int Ed Engl. 2015 Nov 16;54(47):14026-30 [PMID: 26228648]
  128. EBioMedicine. 2020 Jun;56:102821 [PMID: 32505922]
  129. J Pers Med. 2021 Mar 22;11(3): [PMID: 33810037]
  130. Nat Rev Cancer. 2013 Sep;13(9):653-62 [PMID: 23924645]
  131. Biomaterials. 2015 Aug;61:150-61 [PMID: 26002788]
  132. J Control Release. 2004 Jul 7;97(3):477-84 [PMID: 15212879]
  133. ACS Appl Mater Interfaces. 2014 Dec 24;6(24):21859-73 [PMID: 25014486]
  134. Breast Cancer Res Treat. 2008 Mar;108(2):241-50 [PMID: 17476588]
  135. Biotechnol Adv. 2014 Jul-Aug;32(4):693-710 [PMID: 24309541]
  136. J Control Release. 2015 Dec 10;219:205-214 [PMID: 26341694]
  137. J Control Release. 2010 Aug 3;145(3):182-95 [PMID: 20226220]
  138. Adv Mater. 2012 Oct 23;24(40):5476-80 [PMID: 22886872]
  139. Theranostics. 2016 Apr 27;6(7):930-47 [PMID: 27217829]
  140. ACS Nano. 2014 Feb 25;8(2):1161-72 [PMID: 24386876]
  141. Mol Cancer. 2018 Nov 26;17(1):168 [PMID: 30477520]
  142. ACS Nano. 2019 Feb 26;13(2):2357-2369 [PMID: 30699292]
  143. J Control Release. 2014 Sep 28;190:465-76 [PMID: 24993430]
  144. Theranostics. 2017 Oct 13;7(18):4618-4631 [PMID: 29158849]
  145. Sensors (Basel). 2015 Sep 29;15(10):25033-8 [PMID: 26426018]
  146. Angew Chem Int Ed Engl. 2014 Mar 24;53(13):3362-6 [PMID: 24554550]
  147. Int J Nanomedicine. 2012;7:1599-611 [PMID: 22619515]
  148. APL Bioeng. 2019 Mar 26;3(1):011502 [PMID: 31069332]
  149. Macromol Rapid Commun. 2010 Jul 1;31(13):1163-9 [PMID: 21590870]
  150. Adv Mater. 2020 Apr;32(13):e1902604 [PMID: 31353770]
  151. Chem Rev. 2017 Oct 25;117(20):12851-12892 [PMID: 28752995]
  152. Biomacromolecules. 2016 Aug 8;17(8):2507-13 [PMID: 27303825]
  153. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64 [PMID: 20838415]
  154. Acta Biomater. 2017 Oct 15;62:293-305 [PMID: 28842332]
  155. Nat Rev Drug Discov. 2003 May;2(5):347-60 [PMID: 12750738]
  156. Adv Sci (Weinh). 2016 Mar 15;3(7):1500437 [PMID: 27818904]
  157. Adv Mater. 2019 Oct;31(40):e1902409 [PMID: 31369176]
  158. J Biomed Nanotechnol. 2012 Dec;8(6):859-82 [PMID: 23029995]
  159. Small. 2018 Nov;14(44):e1802563 [PMID: 30286280]
  160. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52 [PMID: 24062440]
  161. Expert Opin Drug Deliv. 2021 Feb;18(2):205-227 [PMID: 32969740]
  162. Adv Mater. 2015 Aug 19;27(31):4611-5 [PMID: 26178920]
  163. Molecules. 2020 Aug 15;25(16): [PMID: 32824172]
  164. Front Pharmacol. 2018 Jul 17;9:790 [PMID: 30065653]
  165. Int J Hyperthermia. 2005 Nov;21(7):637-47 [PMID: 16304715]
  166. Nat Rev Cancer. 2006 Sep;6(9):688-701 [PMID: 16900224]
  167. ACS Nano. 2015 Nov 24;9(11):11064-74 [PMID: 26456218]
  168. Invest New Drugs. 2013 Aug;31(4):986-1000 [PMID: 23397498]
  169. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jan;9(1): [PMID: 27312983]
  170. Biomaterials. 2014 Apr;35(13):4213-22 [PMID: 24529391]
  171. Curr Opin Biotechnol. 2013 Dec;24(6):1159-66 [PMID: 23578464]
  172. Nanoscale. 2018 Feb 8;10(6):2856-2865 [PMID: 29364314]
  173. Biomaterials. 2013 Aug;34(26):6272-83 [PMID: 23721796]
  174. J Pers Med. 2021 Feb 14;11(2): [PMID: 33672813]
  175. ACS Nano. 2015 Nov 24;9(11):11023-33 [PMID: 26456489]
  176. Biomater Sci. 2016 Jan;4(1):55-69 [PMID: 26456625]
  177. ACS Nano. 2013 Aug 27;7(8):7011-20 [PMID: 23899347]
  178. Materials (Basel). 2021 Apr 22;14(9): [PMID: 33922291]
  179. Adv Mater. 2016 Sep;28(33):7129-36 [PMID: 27283434]
  180. J Clin Invest. 2015 Sep;125(9):3335-7 [PMID: 26325031]
  181. ACS Nano. 2012 Jan 24;6(1):227-33 [PMID: 22111891]
  182. J Colloid Interface Sci. 2021 Sep 15;598:213-228 [PMID: 33901847]
  183. Macromol Rapid Commun. 2019 Jan;40(2):e1800510 [PMID: 30176080]
  184. J Control Release. 2015 Jul 10;209:77-87 [PMID: 25912408]
  185. Adv Drug Deliv Rev. 2014 Feb;66:2-25 [PMID: 24270007]
  186. P T. 2017 Dec;42(12):742-755 [PMID: 29234213]
  187. Adv Drug Deliv Rev. 2009 Nov 12;61(13):1203-13 [PMID: 19699247]
  188. Chem Rev. 2015 May 13;115(9):3388-432 [PMID: 25914945]
  189. Adv Mater. 2019 Aug;31(34):e1803549 [PMID: 30773699]
  190. AAPS J. 2016 Nov;18(6):1351-1353 [PMID: 27520380]
  191. Theranostics. 2016 Oct 1;6(13):2295-2305 [PMID: 27877235]
  192. Adv Mater. 2021 Apr;33(13):e2008540 [PMID: 33645863]
  193. Biomaterials. 2004 May;25(12):2409-18 [PMID: 14741606]
  194. ACS Appl Mater Interfaces. 2019 Feb 13;11(6):5727-5739 [PMID: 30624889]
  195. Chem Rev. 2014 Jan 8;114(1):367-428 [PMID: 24003911]
  196. ACS Nano. 2017 Feb 28;11(2):2227-2238 [PMID: 28165223]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0polymericstimuli-responsivedrugsnanoparticlesagentscancerpropertiesPolymerictherapytumortargetnanoplatformsnanocarriersapplicationswidelyusedcarriersbioimagingdueexcellentbiocompatibilitybiodegradabilitystructuralversatilityprincipalapplicationmedicineincreasedaccumulationprecisiondeliveryanticancersiteshighersolubilitypharmaceuticallowersystemictoxicityRecentlyattractedattentioncanchangephysicochemicalrespondingstimuliconditionslowpHenzymeredoxhypoxialighttemperaturemagneticfieldultrasoundMoreoveruniquetissuesmaysignificantlyimprovebioactivitydeliveredtreatmentreviewintroducestheranosticsloadingchemicalnucleicimagingmoleculesadditiondiscussstrategydesigningmultifunctionalprovideperspectiveclinicalStimuli-ResponsiveNanoplatformsCancerTherapynanomedicinenanoparticletheranostic

Similar Articles

Cited By